The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics (Q46641684)

23 December 2017

title

The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics (English)

1 reference

23 December 2017

1 reference

1

Anne Katrin Sjølie

1 reference

23 December 2017

Massimo Porta

2

1 reference

23 December 2017

Hans-Henrik Parving

3

1 reference

23 December 2017

Rudy Bilous

4

1 reference

23 December 2017

Ronald Klein

5

1 reference

23 December 2017

DIRECT Programme Study Group

6

1 reference

23 December 2017

publication date

1 March 2005

1 reference

23 December 2017

Journal of the Renin-Angiotensin-Aldosterone System

published in

1 reference

23 December 2017

volume

6

1 reference

23 December 2017

issue

1

1 reference

23 December 2017

page(s)

25-32

1 reference

23 December 2017

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

cites work

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.003

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.003

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.003

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.003

Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.003

Metabolic control and quality of data in medical records for subjects with type 2 diabetes in Swedish primary care: improvement between 1995 and 2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.003

Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.003

Declining incidence of severe retinopathy and persisting decrease of nephropathy in an unselected population of Type 1 diabetes-the Linköping Diabetes Complications Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.003

Incidence of blindness in relation to diabetes. A population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.003

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.003

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.003

Prevention of diabetic renal disease with special reference to microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.003

Impact of blood pressure and antihypertensive treatment on incipient and overt nephropathy, retinopathy, and endothelial permeability in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.003

Candesartan cilexetil is not associated with cough in hypertensive patients with enalapril-induced cough. Multicentre Cough Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.003

The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.003

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.003

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.003

21 January 2018

Identifiers

DOI

10.3317/JRAAS.2005.003

0 references

1 reference

23 December 2017